Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. (December 2022)
- Record Type:
- Journal Article
- Title:
- Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. (December 2022)
- Main Title:
- Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants
- Authors:
- Campos, Daniel Melo de Oliveira
Silva, Maria Karolaynne da
Barbosa, Emmanuel Duarte
Leow, Chiuan Yee
Fulco, Umberto Laino
Oliveira, Jonas Ivan Nobre - Abstract:
- Abstract: The current COVID-19 pandemic, an infectious disease caused by the novel coronavirus (SARS-CoV-2), poses a threat to global health because of its high rate of spread and death. Currently, vaccination is the most effective method to prevent the spread of this disease. In the present study, we developed a novel multiepitope vaccine against SARS-CoV-2 containing Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1) variants. To this end, we performed a robust immunoinformatics approach based on multiple epitopes of the four structural proteins of SARS-CoV-2 (S, M, N, and E) from 475 SARS-CoV-2 genomes sequenced from the regions with the highest number of registered cases, namely the United States, India, Brazil, France, Germany, and the United Kingdom. To investigate the best immunogenic epitopes for linear B cells, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL), we evaluated antigenicity, allergenicity, conservation, immunogenicity, toxicity, human population coverage, IFN-inducing, post-translational modifications, and physicochemical properties. The tertiary structure of a vaccine prototype was predicted, refined, and validated. Through docking experiments, we evaluated its molecular coupling to the key immune receptor Toll-Like Receptor 3 (TLR3). To improve the quality of docking calculations, quantum mechanics/molecular mechanics calculations (QM/MM) were used, with the QM part of the simulations performed using theAbstract: The current COVID-19 pandemic, an infectious disease caused by the novel coronavirus (SARS-CoV-2), poses a threat to global health because of its high rate of spread and death. Currently, vaccination is the most effective method to prevent the spread of this disease. In the present study, we developed a novel multiepitope vaccine against SARS-CoV-2 containing Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1) variants. To this end, we performed a robust immunoinformatics approach based on multiple epitopes of the four structural proteins of SARS-CoV-2 (S, M, N, and E) from 475 SARS-CoV-2 genomes sequenced from the regions with the highest number of registered cases, namely the United States, India, Brazil, France, Germany, and the United Kingdom. To investigate the best immunogenic epitopes for linear B cells, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL), we evaluated antigenicity, allergenicity, conservation, immunogenicity, toxicity, human population coverage, IFN-inducing, post-translational modifications, and physicochemical properties. The tertiary structure of a vaccine prototype was predicted, refined, and validated. Through docking experiments, we evaluated its molecular coupling to the key immune receptor Toll-Like Receptor 3 (TLR3). To improve the quality of docking calculations, quantum mechanics/molecular mechanics calculations (QM/MM) were used, with the QM part of the simulations performed using the density functional theory formalism (DFT). Cloning and codon optimization were performed for the successful expression of the vaccine in E. coli . Finally, we investigated the immunogenic properties and immune response of our SARS-CoV-2 multiepitope vaccine. The results of the simulations show that administering our prototype three times significantly increases the antibody response and decreases the amount of antigens. The proposed vaccine candidate should therefore be tested in clinical trials for its efficacy in neutralizing SARS-CoV-2. Graphical Abstract: ga1 Highlights: This study focuses on the design of a multiepitope peptide vaccine against SARS-CoV-2 and its proteins (S, M, N, and E). 18 epitopes with high anti/immunogenicity, conservation, non-allergenicity, non-toxicity and excellent population coverage. Docking and QM:MM optimization simulations with the TLR-3 receptor confirmed the stability of the constructed vaccine. … (more)
- Is Part Of:
- Computational biology and chemistry. Volume 101(2022)
- Journal:
- Computational biology and chemistry
- Issue:
- Volume 101(2022)
- Issue Display:
- Volume 101, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 101
- Issue:
- 2022
- Issue Sort Value:
- 2022-0101-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12
- Subjects:
- Immunoinformatics -- Quantum mechanics/molecular mechanics calculations -- Multi-epitope vaccine -- SARS-CoV-2 -- Variants
Chemistry -- Data processing -- Periodicals
Biology -- Data processing -- Periodicals
Biochemistry -- Data processing
Biology -- Data processing
Molecular biology -- Data processing
Periodicals
Electronic journals
542.85 - Journal URLs:
- http://www.sciencedirect.com/science/journal/14769271 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.compbiolchem.2022.107754 ↗
- Languages:
- English
- ISSNs:
- 1476-9271
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3390.576700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24382.xml